Difference between revisions of "Team:UCSC/Safety"

 
(24 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
{{UCSC-Header}}
 
{{UCSC-Header}}
 
 
<html>
 
<html>
 +
<meta name="viewport" content="width=device-width, initial-scale=1">
  
 
<script src="https://use.typekit.net/hii0ztv.js"></script>
 
<script src="https://use.typekit.net/hii0ztv.js"></script>
 
<script>try{Typekit.load({ async: true });}catch(e){}</script>
 
<script>try{Typekit.load({ async: true });}catch(e){}</script>
  
<link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css">
+
<!-- <link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css"> -->
  
 
<style>
 
<style>
  
.pageflow {
+
.metabolic-pathway {
   margin-right: 0px;
+
   margin: auto;
  margin-left: 0px;
+
  margin-top:30px;
+
 
   background: honeydew;
 
   background: honeydew;
 +
  width: 100%;
 
}
 
}
  
 
h1 {
 
h1 {
   font-family: 'objektiv-mk1' !important;
+
   font-family: 'objektiv-mk1'!important;
   font-size: 300%;  
+
   font-size: 300%; /*!important*/
 
   font-weight: 300 !important;
 
   font-weight: 300 !important;
 +
    width: 90%;
 
}
 
}
  
 
h2 {
 
h2 {
 
   font-family: 'objektiv-mk1' !important;
 
   font-family: 'objektiv-mk1' !important;
   font-size: 225%;
+
   font-size: 200%;
 
   font-weight: 300;
 
   font-weight: 300;
  margin: -40px;
 
  width: 100%;
 
 
}
 
}
  
Line 34: Line 32:
 
   font-family: 'objektiv-mk1' !important;
 
   font-family: 'objektiv-mk1' !important;
 
   font-size: 200%;
 
   font-size: 200%;
   font-weight: 300;
+
   font-weight: 400;
  padding: 0px !important;
+
 
}
 
}
  
h4 {
+
h4 {
 
   font-family: 'objektiv-mk1' !important;
 
   font-family: 'objektiv-mk1' !important;
   font-size: 125%;
+
   font-size: 150%;
   font-weight: 300;
+
   font-weight: 400;
  text-align: left;
+
  padding-left: 30px
+
 
}
 
}
  
Line 52: Line 47:
 
.proj-button {
 
.proj-button {
 
     position: relative;
 
     position: relative;
     width: 10%;
+
     width: 25%;
 +
    text-decoration: none !important;
 
}
 
}
  
Line 58: Line 54:
 
   opacity: 1;
 
   opacity: 1;
 
   display: inline-block;
 
   display: inline-block;
   width: 14%;
+
   width: 30%;
 +
  height: auto;
 +
  transition: .5s ease;
 +
  backface-visibility: hidden;
 +
}
 +
 
 +
.proj-button-image-solo {
 +
  opacity: 1;
 +
  display: inline-block;
 +
  width: 65%;
 
   height: auto;
 
   height: auto;
 
   transition: .5s ease;
 
   transition: .5s ease;
Line 73: Line 78:
 
   transform: translate(-50%, -50%);
 
   transform: translate(-50%, -50%);
 
   -ms-transform: translate(-50%, -50%)
 
   -ms-transform: translate(-50%, -50%)
 +
}
 +
 +
.overlap-button-text {
 +
  background-color: transparent;
 +
  color: black;
 +
  font-size: 20px;
 +
  font-family: "Objektiv-mk1" !important;
 +
  font-weight: 400 !important;
 +
  padding: 16px 32px;
 
}
 
}
  
 
.proj-button:hover .proj-button-image {
 
.proj-button:hover .proj-button-image {
 +
  opacity: 0.3;
 +
}
 +
 +
.proj-button:hover .proj-button-image-solo {
 
   opacity: 0.3;
 
   opacity: 0.3;
 
}
 
}
Line 88: Line 106:
 
   font-size: 20px;
 
   font-size: 20px;
 
   font-family: "Objektiv-mk1" !important;
 
   font-family: "Objektiv-mk1" !important;
   font-weight: 600 !important;
+
   font-weight: 400 !important;
 
   padding: 16px 32px;
 
   padding: 16px 32px;
 
}
 
}
  
.pagagraph {
+
.text {
   font-family: 'objektiv-mk1' !important;
+
   background-color: transparent;
 
+
  color: black;
 +
  font-size: 20px;
 +
  padding: 16px 32px;
 
}
 
}
  
.reference-list {
+
.paragraph-left {
   font-family: 'objektiv-mk1';
+
   font-family: 'objektiv-mk1' !important;
   font-size: 12px;
+
   font-size: 18px;
 
   text-align: left;
 
   text-align: left;
   list-style-type: none;
+
   vertical-align: middle;
  line-height: 100%;
+
  margin-bottom: 80px;
+
 
}
 
}
  
 
p {
 
p {
 
   font-family: 'objektiv-mk1' !important;
 
   font-family: 'objektiv-mk1' !important;
 +
/*  margin-left: 200px !important;
 +
  margin-right: 200px !important;*/
 
   font-size: large !important;
 
   font-size: large !important;
 
}
 
}
Line 113: Line 133:
 
.firstword {
 
.firstword {
 
   font-family: 'objektiv-mk1' !important;
 
   font-family: 'objektiv-mk1' !important;
   font-size: 70px;
+
   font-size: 65px;
 +
}
 +
.quote {
 +
  font-family: 'objektiv-mk1' !important;
 +
  font-style: italic !important;
 +
  font-size: 28px;
 +
  line-height: 130%;
 +
}
 +
 
 +
.quote-person {
 +
  font-family: 'objektiv-mk1' !important;
 +
  font-size: 22px;
 +
  width: 100% !important;
 +
  text-align: right !important;
 +
  padding-right: 80px !important;
 
}
 
}
  
 
.titleimg {
 
.titleimg {
 
   vertical-align: middle;
 
   vertical-align: middle;
   width: 14%;
+
   width: 17%;
 
}
 
}
  
 
.titlebox {
 
.titlebox {
   margin-left: 200px !important;
+
   margin-left: 0px !important;
 
}
 
}
  
.in-text-image {
+
.reference-list {
   width: 100%;
+
   font-family: 'objektiv-mk1';
   vertical-align: middle;
+
   font-size: 12px;
   margin: 0px;
+
  text-align: left;
 +
  list-style-type: none;
 +
  line-height: 100%;
 +
   margin-bottom: 80px;
 
}
 
}
 +
 +
.reference-italic {
 +
  font-family: 'objektiv-mk1';
 +
  font-size: 12px;
 +
  font-style: italic;
 +
}
 +
 +
figcaption {
 +
  font-family: 'objektiv-mk1';
 +
  font-style: italic;
 +
  font-size: 13px;
 +
}
 +
  
 
@media (min-width: 1144px) {
 
@media (min-width: 1144px) {
 
   .container {
 
   .container {
    width: 100% !important;
+
      width: 100% !important;
  }
+
    }
 +
 
 
   .text-container {
 
   .text-container {
     width: 80%;
+
     width: 70%;
 
     padding-left: 15px;
 
     padding-left: 15px;
 
     padding-right: 15px;
 
     padding-right: 15px;
 
   }
 
   }
 +
 
   .titlebox {
 
   .titlebox {
 
     width: 80%;
 
     width: 80%;
Line 151: Line 203:
 
@media (max-width: 1144px) {
 
@media (max-width: 1144px) {
  
  .titlebox {
+
    .titlebox {
     margin-left: auto !important;
+
      margin-left: auto !important;
 +
    }
 +
 
 +
  p {
 +
    font-family: 'objektiv-mk1' !important;
 +
     margin-left: 10px !important;
 +
    margin-right: 10px !important;
 +
    font-size: medium !important;
 +
  }
 +
 
 +
  .quote {
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-style: italic !important;
 +
    font-size: 26px;
 +
  }
 +
 
 +
  .quote-person {
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-size: 20px;
 +
    width: 100%;
 +
    text-align: right;
 +
    padding-right: 80px !important;
 +
  }
 +
 
 +
  .metabolic-pathway {
 +
      margin: auto;
 +
      background: honeydew;
 +
      width: 100%;
 +
  }
 +
 
 +
  .container {
 +
    width: 80% !important;
 +
    padding-left: 0px !important;
 +
    padding-right: 0px !important;
 
   }
 
   }
  
 
   .text-container {
 
   .text-container {
 
     width: 80%;
 
     width: 80%;
     padding-left: 15px;
+
     padding-left: 0px;
     padding-right: 15px;
+
     padding-right: 0px;
 
   }
 
   }
  
.titleimg {
+
  figcaption {
  vertical-align: middle;
+
    font-size: 14px;
   width: 20%;
+
   }
 
}
 
}
  
  p {
+
@media (max-width: 992px) {
    font-family: 'objektiv-mk1' !important;
+
  .proj-button-image-solo {
    margin-left: 20px !important;
+
      opacity: 1;
    margin-right: 20px !important;
+
      display: inline-block;
    font-size: medium !important;
+
      width: 30%;
  }
+
      height: auto;
 +
      transition: .5s ease;
 +
      backface-visibility: hidden;
 +
    }
 
}
 
}
  
Line 178: Line 266:
 
       opacity: 1;
 
       opacity: 1;
 
       display: inline-block;
 
       display: inline-block;
       width: 40%;
+
       width: 32%;
 +
      height: auto;
 +
      transition: .5s ease;
 +
      backface-visibility: hidden;
 +
    }
 +
 
 +
    .proj-button-image-solo {
 +
      opacity: 1;
 +
      display: inline-block;
 +
      width: 35%;
 
       height: auto;
 
       height: auto;
 
       transition: .5s ease;
 
       transition: .5s ease;
Line 192: Line 289:
 
       transform: translate(-50%, -50%);
 
       transform: translate(-50%, -50%);
 
       -ms-transform: translate(-50%, -50%)
 
       -ms-transform: translate(-50%, -50%)
 +
  }
 +
 +
  .overlap-button-text {
 +
    background-color: rgba(94, 94, 94, 0.4);
 +
    border-radius: 60px;
 +
    color: white;
 
   }
 
   }
  
 
   h1 {
 
   h1 {
 
       font-family: 'objektiv-mk1'; /*!important*/
 
       font-family: 'objektiv-mk1'; /*!important*/
       font-size: 300%; /*!important*/
+
       font-size: 220%; /*!important*/
 +
      width: 80%;
 
   }
 
   }
  
  h2 {
+
    h2 {
 
       font-family: 'objektiv-mk1'; /*!important*/
 
       font-family: 'objektiv-mk1'; /*!important*/
       font-size: 225%; /*!important*/
+
       font-size: 34px; /*!important*/
 
   }
 
   }
  
   .text-container {
+
   h4 {
     width: 80%;
+
  font-family: 'objektiv-mk1' !important;
 +
  font-size: 150%;
 +
  font-weight: 400;
 +
  }
 +
 
 +
  .quote {
 +
     font-family: 'objektiv-mk1' !important;
 +
    font-style: italic !important;
 +
    font-size: 20px;
 
   }
 
   }
  
   .in-text-image {
+
   .quote-person {
 
     width: 100%;
 
     width: 100%;
     vertical-align: middle;
+
     font-family: 'objektiv-mk1' !important;
     margin: 15px;
+
    font-size: 16px;
 +
    text-align: right !important;
 +
     padding-right: 20px !important;
 
   }
 
   }
  
   /*.col-md-1 {
+
   .text-container {
     width: 0%;
+
     width: 82%;
 +
    padding-left: 0px;
 +
    padding-right: 0px;
 
   }
 
   }
  
   .col-md-5 {
+
   figcaption {
     margin-bottom: 45px;
+
     font-size: 14px;
 +
    line-height: 140%;
 
   }
 
   }
  
   .col-md-6 {
+
   .reference-list {
     margin-bottom: 15px;
+
     font-family: 'objektiv-mk1';
     width: 80%
+
     font-size: 12px;
  }*/
+
    text-align: left;
 
+
    list-style-type: none;
@media (max-width: 576px) {
+
    line-height: 100%;
 
+
    margin-bottom: 80px;
  h1 {
+
    margin-right: -70px;
     font-size: 250%;
+
     margin-left: -70px;
 
   }
 
   }
 +
}
 +
/*  p {
 +
    margin-left: 10px !important;
 +
    margin-right: 10px !important;
 +
  }
 +
}*/
  
  /*img {
+
@media (max-width: 576px) {
    padding: 15px;
+
  }*/
+
 
+
 
   .proj-button-image {
 
   .proj-button-image {
 
       opacity: 1;
 
       opacity: 1;
 
       display: inline-block;
 
       display: inline-block;
       width: 60%;
+
       width: 50%;
 +
      height: auto;
 +
      transition: .5s ease;
 +
      backface-visibility: hidden;
 +
    }
 +
 
 +
    .proj-button-image-solo {
 +
      opacity: 1;
 +
      display: inline-block;
 +
      width: 50%;
 
       height: auto;
 
       height: auto;
 
       transition: .5s ease;
 
       transition: .5s ease;
Line 254: Line 383:
 
       transform: translate(-50%, -50%);
 
       transform: translate(-50%, -50%);
 
       -ms-transform: translate(-50%, -50%)
 
       -ms-transform: translate(-50%, -50%)
 +
  }
 +
 +
    .overlap-button-text {
 +
    background-color: rgba(94, 94, 94, 0.5);
 +
    border-radius: 60px;
 +
    color: white;
 +
    font-size: 12px;
 
   }
 
   }
  
Line 264: Line 400:
 
     vertical-align: middle;
 
     vertical-align: middle;
 
     width: 40%;
 
     width: 40%;
  }
 
 
  .text-container {
 
    width: 100%;
 
    margin-left: -15px;
 
    margin-right: -15px;
 
 
   }
 
   }
  
Line 279: Line 409:
 
   }
 
   }
  
   .col-md-6 {
+
   h1 {
     margin-bottom: 20px;
+
     font-size: 160%;
    margin-top: 15px;
+
 
   }
 
   }
  
   .col-md-5 {
+
   .quote {
     margin-bottom: 15px;
+
    font-family: 'objektiv-mk1' !important;
 +
    font-style: italic !important;
 +
    font-size: 17px;
 +
  }
 +
 
 +
  .quote-person {
 +
    width: 60% !important;
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-size: 12px;
 +
    text-align: right !important;
 +
    margin-right: -120px !important;
 +
  }
 +
 
 +
  .paragraph-left {
 +
    font-size: 13px;
 +
    line-height: 170%;
 +
  }
 +
 
 +
  .text-container {
 +
    width: 85%;
 +
    padding-left: 0px;
 +
    padding-right: 0px;
 +
  }
 +
 
 +
  .metabolic-pathway {
 +
      margin: auto;
 +
      background: honeydew;
 +
      width: 110%;
 +
      margin-left: -20px;
 +
      margin-right: -20px;
 +
  }
 +
 
 +
  figcaption {
 +
    font-size: 12px;
 +
    line-height: 130%;
 +
  }
 +
 
 +
  .reference-list {
 +
    font-family: 'objektiv-mk1';
 +
    font-size: 12px;
 +
    text-align: left;
 +
    list-style-type: none;
 +
    line-height: 100%;
 +
     margin-bottom: 80px;
 +
    margin-right: -50px;
 +
    margin-left: -50px;
 +
  }
 +
}
 +
 
 +
@media (max-width: 420px) {
 +
  h3 {
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-size: 155%;
 +
    font-weight: 400;
 +
  }
 +
}
 +
 
 +
@media (max-width: 400px) {
 +
  .quote {
 +
    font-size: 15px;
 
   }
 
   }
 
}
 
}
Line 313: Line 501:
 
</style>
 
</style>
  
 
+
<body style="background-color: honeydew;">
<body>
+
 
<div id="page">
 
<div id="page">
 
<center>
 
<center>
 
<br>
 
<br>
  
<img class="titleimg" src="https://static.igem.org/mediawiki/2017/3/37/Gloves.png">
+
<img class="titleimg" src="https://static.igem.org/mediawiki/2017/3/37/Gloves.png" alt="http://freevector.co/vector-icons/fashion/protection-gloves.html">
  
<h1>SAFETY</h1><br><br>
+
<h1>SAFETY</h1>
 +
 
 +
<br>
 +
<br>
  
 
<div class="text-container">
 
<div class="text-container">
   <p><span class="firstword">When</span> choosing an organism to help us produce acetaminophen and vitamin B-12 we sought out an FDA approved microbe; however, we resorted to using a non-toxic cyanobacteria as a model for spirulina. Spirulina is generally recognized as safe organism and our genes were chosen from bio-safety level 1 (BSL-1) organisms.</p>
+
   <p><span class="firstword">When</span> choosing an organism to help us produce acetaminophen and vitamin B<sub>12</sub> we sought out an FDA-approved microbe; however, we resorted to using a non-toxic cyanobacteria, <i>Synechococcus elongatus</i> strain PCC 7942, as a model for <i>Arthrospira platensis</i>. <i>A. platensis</i> is a generally recognized as safe organism and our genes were chosen from bio-safety level 1 (BSL-1) organisms.</p>
  
  
 
   <div class="container">
 
   <div class="container">
 
       <div class="row">
 
       <div class="row">
           <h2><b>L A B</b> SAFETY</h2><br>
+
           <h2><b>L A B</b> SAFETY</h2>
 +
          <br>
 
           <div class="col-md-1"></div>
 
           <div class="col-md-1"></div>
 
           <div class="col-md-5">
 
           <div class="col-md-5">
Line 336: Line 527:
 
       <!-- </div> -->
 
       <!-- </div> -->
 
           <div class="col-md-5">
 
           <div class="col-md-5">
             <br><br><br><br><br>
+
             <br><br><br><br>
 
           <p>Proper PPE for BSL-1 organisms are worn in our laboratory. Within the lab space, every person is expected to be wearing gloves, long pants, close-toed shoes, a lab coat, and protective goggles. All personnel also must be accompanied with one other person so that there is no one alone in lab.
 
           <p>Proper PPE for BSL-1 organisms are worn in our laboratory. Within the lab space, every person is expected to be wearing gloves, long pants, close-toed shoes, a lab coat, and protective goggles. All personnel also must be accompanied with one other person so that there is no one alone in lab.
 
           </p>
 
           </p>
Line 345: Line 536:
 
<br>
 
<br>
  
<h2><b>P R O J E C T</b> SAFETY</h2><br>  
+
<h2><b>P R O J E C T</b> SAFETY</h2>
 +
 
 +
<br>  
 
            
 
            
<p>We are growing two different strains of <i>S. elongatus</i>: 7002 and 7942. While PCC 7942 will act as our host organism due to its metabolic similarity to <i>A. platensis</i>, we plan to use PCC 7002, which requires external B12 for survival, as a growth reference for the detection of vitamin B12. PCC 7942 was obtained from the University of California, San Diego (UCSD) iGEM team and PCC 7002 was obtained from Dr. Donald Bryant at Pennsylvania State University.<p><br>
+
<!--<p>We are growing two different strains of <i>S. elongatus</i>: 7002 and 7942. While PCC 7942 will act as our host organism due to its metabolic similarity to <i>A. platensis</i>, we plan to use PCC 7002, which requires external B<sub>12</sub> for survival, as a growth reference for the detection of vitamin B<sub>12</sub>. PCC 7942 was obtained from the University of California, San Diego (UCSD) iGEM team and PCC 7002 was obtained from Dr. Donald Bryant at Pennsylvania State University.</p>-->
  
<h3>VITAMIN B-12</h3>
+
<h3>VITAMIN B<sub>12</sub></h3>
  
<h4><b>G E N E S</b> U S E D:<h4>
+
<br>
 +
 
 +
<h4 style="text-align: left;"><b>G E N E S</b> U S E D:</h4>
 +
 
 +
<br>
  
<p style="
+
<p style="padding-left: 30px; padding-right: 30px;"><b>I. <i>ssuE</i></b> --> produces FMN reductase<br><br>
    padding-left: 30px;
+
    padding-right: 30px;
+
"><b>I. <i>ssuE</i></b> => produces FMN reductase<br><br>
+
 
   
 
   
           Organism: <i>Synechoccocous elongatus</i> strain PCC 7002<br>
+
           Organism: <i>Synechoccocous elongatus</i> strain PCC 7002
           Biosafety <b>Level I</b><br><br>
+
          <br>
 +
           Biosafety <b>Level I</b>
 +
          <br>
 +
          <br>
 
   
 
   
The synthesis of 5,6-DMB first requires the presence of reduced flavin mononucleotide (FMNH2). FMNH2 is reduced from flavin mononucleotide (FMN) by FMN reductase, which is encoded with the ssuE gene [19,20].<br><br>
+
          The synthesis of 5,6-DMB first requires the presence of reduced flavin mononucleotide (FMNH<sub>2</sub>). FMNH<sub>2</sub> is reduced from flavin mononucleotide (FMN) by FMN reductase, which is encoded with the <i>ssuE</i> gene<sup>[19,20]</sup>.
 +
          <br>
 +
          <br>
  
FMNH2 + NADP+ = FMN + NADPH<br><br>
+
          FMNH<sub>2</sub> + NADP<sup>+</sup> = FMN + NADPH
 +
          <br>
 +
          <br>
 
   
 
   
<b>II. <i>bluB</i></b> => 5,6-DMB synthase<br><br>
+
          <b>II. <i>bluB</i></b> --> 5,6-DMB synthase
 +
          <br>
 +
          <br>
  
           Organism: <i>Sinorhizobium meliloti</i> 1021<br>
+
           Organism: <i>Sinorhizobium meliloti</i> 1021
 +
          <br>
 
           Biosafety <b>Level I</b>
 
           Biosafety <b>Level I</b>
 
</p>
 
</p>
 +
 +
<br>
 +
<br>
  
 
<h3>ACETAMINOPHEN</h3>
 
<h3>ACETAMINOPHEN</h3>
  
<h4><b>G E N E S</b>  U S E D:<h4>
+
<br>
  
<p style="
+
<h4 style="text-align: left;"><b>G E N E S</b>  U S E D:</h4>
    padding-left: 30px;
+
    padding-right: 30px;
+
"><b>I. <i>4ABH</i></b> => 4-aminophenol<br><br>
+
   
+
          Organism: <i>Agaricus bisporus</i><br>
+
          Biosafety <b>Level I</b><br><br>
+
+
<b>II. <i>nhoA</i></b> => converts 4-aminophenol into acetaminophen<br><br>
+
  
          Organism: <i>Escherichia coli</i><br>
+
<br>
          Biosafety <b>Level I</b><br><br><br>
+
</p>
+
+
  
 +
<p style="padding-left: 30px; padding-right: 30px;"><b>I. <i>4ABH</i></b> --> 4-aminophenol<br><br>
 
   
 
   
<h3><b>T O X I C I T Y</b> TESTS</h3><br>
+
          Organism: <i>Agaricus bisporus</i>
 +
          <br>
 +
          Biosafety <b>Level I</b>
 +
          <br>
 +
          <br>
 
   
 
   
<p>In order to judge whether our project would possibly be safe for consumption, we performed toxicity tests for the acetaminophen pathway in PCC 7942. Varying amounts of acetaminophen were added to liquid culture and the OD of each sample was observed. Liquid culture samples containing 1.32 mM, 6.62 mM, and 13.23 mM of acetaminophen were left to oxidize overnight and the color change was compared with liquid cultures samples containing similar concentrations of 4-aminophenol.</p><br>
+
          <b>II. <i>nhoA</i></b> --> converts 4-aminophenol into acetaminophen
 +
          <br>
 +
          <br>
  
<div class="container">
+
          Organism: <i>Escherichia coli</i>
  <div class="reference-list">
+
          <br>
    <hr>
+
          Biosafety <b>Level I</b>
 +
          <br>
 +
          <br>
 +
          <br>
 +
</p>
  
      <li>[19] R. Caspi, T. Altman, J. M. Dale, K. Dreher, C. A. Fulcher, F. Gilham, P. Kaipa, A. S. Karthikeyan, A. Kothari, M. Krummenacker, M. Latendresse, L. A. Mueller, S. Paley, L. Popescu, A. Pujar, A. G. Shearer, P. Zhang, and P. D. Karp, “The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases,” Nucleic Acids Research, vol. 38, pp. D473–D479, Jan. 2010.</li>
+
<!-- 
 +
<h3><b>T O X I C I T Y</b>  TESTS</h3>
  
 +
<br>
 +
 +
<p>In order to judge whether our project would possibly be safe for consumption, we performed toxicity tests for the acetaminophen pathway in PCC 7942. Varying amounts of acetaminophen were added to liquid culture and the OD of each sample was observed. Liquid culture samples containing 1.32 mM, 6.62 mM, and 13.23 mM of acetaminophen were left to oxidize overnight and the color change was compared with liquid cultures samples containing similar concentrations of 4-aminophenol.</p> -->
 
<br>
 
<br>
  
       <li>[20] “ssuE - FMN reductase (NADPH) - Escherichia coli (strain K12) - ssuE gene & protein.”
+
  <div class="container">
       </li>
+
    <div class="container">
 +
       <div class="reference-list">
 +
      <hr>
 +
          <li>[19] R. Caspi, T. Altman, J. M. Dale, K. Dreher, C. A. Fulcher, F. Gilham, P. Kaipa, A. S. Karthikeyan, A. Kothari, M. Krummenacker, M. Latendresse, L. A. Mueller, S. Paley, L. Popescu, A. Pujar, A. G. Shearer, P. Zhang, and P. D. Karp, “The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases,” Nucleic Acids Research, vol. 38, pp. D473–D479, Jan. 2010.</li>
 +
          <li>[20] “ssuE - FMN reductase (NADPH) - Escherichia coli (strain K12) - ssuE gene & protein.”</li>
 +
       </div>
 +
    </div>
  
</div>
+
<br>
</div>
+
<br>
+
  
 
</div>
 
</div>
 +
</center>
 +
</div>
 +
</body>
 
</html>
 
</html>
 
 
{{UCSC-Footer}}
 
{{UCSC-Footer}}

Latest revision as of 23:58, 1 November 2017


http://freevector.co/vector-icons/fashion/protection-gloves.html

SAFETY



When choosing an organism to help us produce acetaminophen and vitamin B12 we sought out an FDA-approved microbe; however, we resorted to using a non-toxic cyanobacteria, Synechococcus elongatus strain PCC 7942, as a model for Arthrospira platensis. A. platensis is a generally recognized as safe organism and our genes were chosen from bio-safety level 1 (BSL-1) organisms.

L A B SAFETY






Proper PPE for BSL-1 organisms are worn in our laboratory. Within the lab space, every person is expected to be wearing gloves, long pants, close-toed shoes, a lab coat, and protective goggles. All personnel also must be accompanied with one other person so that there is no one alone in lab.





P R O J E C T SAFETY


VITAMIN B12


G E N E S U S E D:


I. ssuE --> produces FMN reductase

Organism: Synechoccocous elongatus strain PCC 7002
Biosafety Level I

The synthesis of 5,6-DMB first requires the presence of reduced flavin mononucleotide (FMNH2). FMNH2 is reduced from flavin mononucleotide (FMN) by FMN reductase, which is encoded with the ssuE gene[19,20].

FMNH2 + NADP+ = FMN + NADPH

II. bluB --> 5,6-DMB synthase

Organism: Sinorhizobium meliloti 1021
Biosafety Level I



ACETAMINOPHEN


G E N E S U S E D:


I. 4ABH --> 4-aminophenol

Organism: Agaricus bisporus
Biosafety Level I

II. nhoA --> converts 4-aminophenol into acetaminophen

Organism: Escherichia coli
Biosafety Level I




  • [19] R. Caspi, T. Altman, J. M. Dale, K. Dreher, C. A. Fulcher, F. Gilham, P. Kaipa, A. S. Karthikeyan, A. Kothari, M. Krummenacker, M. Latendresse, L. A. Mueller, S. Paley, L. Popescu, A. Pujar, A. G. Shearer, P. Zhang, and P. D. Karp, “The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases,” Nucleic Acids Research, vol. 38, pp. D473–D479, Jan. 2010.
  • [20] “ssuE - FMN reductase (NADPH) - Escherichia coli (strain K12) - ssuE gene & protein.”